Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Beta blockers, renin-angiotensin inhibitors may thwart anthracycline-induced cardiotoxicity

Jairia Dela Cruz
05 Dec 2018

Beta blockers (BBs) and/or renin-angiotensin inhibitors (RAIs) appear to be useful for preventing cardiotoxicity from anthracycline exposure, according to the results of a systematic review and meta-analysis presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.

“Anthracyclines constitute the backbone of several chemotherapy regimens for various cancers. The use of these agents is constrained by the dose-limiting adverse effect of these drugs on cardiac function,” the investigators said.

“Two cornerstones of heart failure treatment, BB and RAI, have been used in studies to prevent cardiotoxicity from anthracycline exposure,” they continued.

To review and summarize extant evidence on the effectiveness of the said drugs in the prevention of anthracycline-induced cardiotoxicity, the investigators pooled data from 10 trials evaluating RAI and/or BB vs placebo as prophylaxis for cardiac events and left ventricular ejection fraction (LVEF) reduction in adult cancer patients (n=752) with normal ejection fraction and without heart failure symptoms on anthracycline.

Results showed that RAI and/or BB led to a statistically significant preservation of LVEF compared with placebo (mean difference [MD], 2.62 percent; 95 percent CI, 2.14–3.10; p<0.00001; I2, 90 percent). The benefits were consistent across the RAI (MD, 2.35 percent; 1.29–3.40; p<0.0001; I2, 88 percent) and BB (MD, 1.65 percent; 0.7–2.60; p=0.0007; I2, 92 percent) monotherapy arms. [ESMO Asia 2018, abstract 438P]

In a preplanned analysis of cardiac events, BBs and/or RAIs were also associated with a reduced risk of cardiac mortality or heart failure (relative risk, 0.27; 0.09–0.77; p=0.01; I2, 0 percent).

The present data indicate that BB and/or RAI can be used to preserve LVEF and reduce cardiac events among cancer patients receiving anthracyclines, the investigators said.

“Differences between populations studied explain the high heterogeneity from all the studies,” they added.

In the prevention and management of cancer therapy-induced left ventricular dysfunction, guidelines provide a useful framework: identify high-risk patients, treat their cardiovascular risk factors, modify anthracycline and radiation delivery, and administration of prophylaxis. [J Clin Oncol 2017;35:893-911; Eur Heart J 2016;37:2768-2801; Circulation 2013;128:e240-e327]

However, experts noted the need for continued study as new targeted cancer therapies become available clinically with undetermined short- and long-term cardiac effects. Also, there are currently no guidelines to direct which patients should or should not continue their cancer treatment, although the nature of the disease and treatment limit the ability to construct robust trials in this area. [https://www.acc.org/latest-in-cardiology/articles/2018/10/30/09/08/management-of-cancer-therapy-induced-lv-dysfunction]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.